POD1UM-303/InterAACT 2
30 Nov 2021
Trial Summary
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Acronym:
POD1UM-303/InterAACT 2
ACTRN/NCT /ethics:
NCT04472429
Scientific title:
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Sponsor / Cooperative group:
Incyte Corporation
Trial & Patient Characteristics
| Cancer Type | Bowel and colon |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2020-11-09 |
| Anticipated End Date | 2024-10-24 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Amitesh Roy |
| Recruitment Status | Recruiting |